EWTX$38.090.05%-0.02
Edgewise Therapeutics Inc (EWTX)
Date: 2026-11-03 16:00O: 38.73H: 40.41L: 36.70C: 38.15Vol: 1.048M
Edgewise Therapeutics Inc stock is traded at $38.09, with a volume of 1,059,389. It is down -0.05% in the last 24 hours and down -8.00% over the past month. Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.
Previous Close:
$38.11
Open:
$38.73
24h Volume:
1,059,389
Relative Volume:
0.81
Market Cap:
$4.14B
Revenue:
-
Net Income/Loss:
-$176.01M
P/E Ratio:
-
EPS:
-$1.66
Net Cash Flow:
-$148.97M
1W Performance:
-3.64%
1M Performance:
-8.00%
6M Performance:
+24.44%
1Y Performance:
+111.96%
1-Day Range:
$36.70$40.41
1-Week Range:
$37.46$41.63
52-Week Range:
$16.70$48.51
Edgewise Therapeutics Inc Stock (EWTX) Company Profile
Name
Edgewise Therapeutics IncSector
HealthcareIndustry
BiotechnologyPhone
720-262-7002Address
1715 38TH ST, BOULDER, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS
Edgewise Therapeutics Inc Stock (EWTX) Upgrades & Downgrades
Edgewise Therapeutics Inc Stock (EWTX) Financials Data
Edgewise Therapeutics Inc Stock (EWTX) Insider Trading
- JOANNE DONOVANAug 13 '26Officer
- Transaction
- Proposed Sale
- Cost
- $43.56
- #Shares
- 2,919
- Value ($)
- 127,152
- #Shares Total
- 0
- Donovan Joanne M.Aug 13 '26CMO
- Transaction
- Sale
- Cost
- $43.41
- #Shares
- 2,919
- Value ($)
- 126,704
- #Shares Total
- 8,625
- MOORE JOHN RAug 12 '26General Counsel
- Transaction
- Sale
- Cost
- $43.82
- #Shares
- 5,016
- Value ($)
- 219,823
- #Shares Total
- 17,697
- Derakhshan BehradAug 12 '26Chief Business Officer
- Transaction
- Option Exercise
- Cost
- $0.00
- #Shares
- 13,281
- Value ($)
- 0
- #Shares Total
- 36,926
- Derakhshan BehradAug 12 '26Chief Business Officer
- Transaction
- Sale
- Cost
- $43.81
- #Shares
- 5,100
- Value ($)
- 223,424
- #Shares Total
- 31,826
- KOCH KEVINAug 12 '26President and CEO
- Transaction
- Option Exercise
- Cost
- $0.00
- #Shares
- 39,844
- Value ($)
- 0
- #Shares Total
- 70,459
- KOCH KEVINAug 12 '26President and CEO
- Transaction
- Sale
- Cost
- $43.68
- #Shares
- 17,971
- Value ($)
- 785,042
- #Shares Total
- 52,488
- Russell Alan JAug 12 '26Chief Scientific Officer
- Transaction
- Sale
- Cost
- $43.73
- #Shares
- 5,901
- Value ($)
- 258,042
- #Shares Total
- 31,466
- MOORE JOHN RAug 12 '26General Counsel
- Transaction
- Option Exercise
- Cost
- $0.00
- #Shares
- 12,499
- Value ($)
- 0
- #Shares Total
- 22,713
- Donovan Joanne M.Aug 12 '26CMO
- Transaction
- Sale
- Cost
- $43.85
- #Shares
- 6,522
- Value ($)
- 286,000
- #Shares Total
- 11,544
